<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">McInnes, Iain B.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Targets in Rheumatoid Arthritis: SYK, JAKs, and BTK</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the mechanisms of kinase inhibitors, on the targeted new therapies for rheumatoid arthritis, and is designed to inform clinicians about this new class of compounds and summarize key early studies to help guide clinical decision-making in the future.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>